Who are Velsipity's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Etrasimod, Zeposia, Mayzent, Gilenya.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/velsipity.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Velsipity — Competitive Intelligence Brief

Velsipity (Etrasimod Arginine) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sphingosine 1-phosphate receptor modulator. Area: Immunology.

marketed Sphingosine 1-phosphate receptor modulator Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5 Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Velsipity (Etrasimod Arginine) — Pfizer Inc.. Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Velsipity TARGET	Etrasimod Arginine	Pfizer Inc.	marketed	Sphingosine 1-phosphate receptor modulator	Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5
Etrasimod	etrasimod	Pfizer	marketed	Sphingosine 1-phosphate receptor modulator	Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5	2023-01-01
Zeposia	OZANIMOD	Bristol-Myers Squibb	marketed	Sphingosine 1-phosphate Receptor Modulator	Sphingosine 1-phosphate receptor 1	2020-01-01
Mayzent	SIPONIMOD	Novartis	marketed	Sphingosine 1-phosphate Receptor Modulator [EPC]	Sphingosine 1-phosphate receptor 1	2019-01-01
Gilenya	FINGOLIMOD	Novartis	marketed	Sphingosine 1-phosphate Receptor Modulator	Sphingosine 1-phosphate receptor 1	2010-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sphingosine 1-phosphate receptor modulator class)

OrphAI Therapeutics · 1 drug in this class
Pfizer · 1 drug in this class
Pfizer Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Velsipity — Competitive Intelligence Brief. https://druglandscape.com/ci/velsipity. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab